Clinical Trials Logo

Primary Hypercholesterolemia clinical trials

View clinical trials related to Primary Hypercholesterolemia.

Filter by:

NCT ID: NCT03413462 Completed - Clinical trials for Primary Hypercholesterolemia

Efficacy and Safety Study of HS-25 in Chinese Adults With Primary Hypercholesterolemia

HS-25-III-01
Start date: April 12, 2016
Phase: Phase 3
Study type: Interventional

To determine the efficacy of HS-25 (20mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 12-week period of treatment in adults with primary hypercholesterolemia; To determine the safety of HS-25 (20mg) in subjects with LDL-C

NCT ID: NCT02941848 Completed - Clinical trials for Primary Hypercholesterolemia

Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers

Start date: November 2014
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate Pharmacokinetic Properties and Safety after administration of HCP1306 tablet and Co-administration of HGP0816 tablet, HGP1404 tablet in the healthy adults.

NCT ID: NCT02445352 Completed - Clinical trials for Primary Hypercholesterolemia

Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia

ROSE
Start date: July 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of DP-R207 in patients with primary hypercholesterolemia.

NCT ID: NCT02205606 Completed - Clinical trials for Primary Hypercholesterolemia

Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia

Start date: June 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate efficacy and safety of HCP1306 in patients with primary hypercholesterolemia.

NCT ID: NCT02087917 Completed - Clinical trials for Primary Hypercholesterolemia

A 4-week, Randomized, Placebo-Controlled, Double-Blind, Efficacy and Safety Study of HS-25 in Adults With Primary Hypercholesterolemia

Start date: March 2014
Phase: Phase 2
Study type: Interventional

To determine the efficacy of HS-25 (5, 10, 20 or 30 mg) in reducing low density lipoprotein-cholesterol (LDL-C) levels after a 4-week period of treatment in adults with primary hypercholesterolemia.

NCT ID: NCT01879319 Completed - Clinical trials for Primary Hypercholesterolemia

Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen

Start date: July 11, 2013
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in a home-use setting using either an automated mini-doser (AMD) or autoinjector/pen (AI/pen).

NCT ID: NCT01849497 Completed - Clinical trials for Primary Hypercholesterolemia

Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen

Start date: April 18, 2013
Phase: Phase 3
Study type: Interventional

The primary objective of this study was to assess users' ability to administer a full dose of evolocumab in home-use using either a pre-filled syringe or autoinjector/pen.

NCT ID: NCT01012219 Completed - Clinical trials for Primary Hypercholesterolemia

A Study to Evaluate the Effects of Laropiprant on the Antiplatelet Effects of Clopidogrel and Aspirin in Combination (MK-0524A-114)(COMPLETED)

Start date: November 2009
Phase: Phase 1
Study type: Interventional

This is a 3-period study. Periods 1 and 2 will evaluate the effects of multiple doses of laropiprant on the antiplatelet effects of clopidogrel and aspirin administered in combination in participants with primary hypercholesterolemia or mixed dyslipidemia. Period 3 will be open-label and will evaluate single dose pharmacokinetics of nicotinic acid and laropiprant components of Tredaptive.

NCT ID: NCT00941603 Completed - Clinical trials for Primary Hypercholesterolemia

Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)

Start date: June 29, 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of SCH 900271 compared to placebo on the reduction of low-density lipoprotein cholesterol (LDL-C) from baseline to 8 weeks of treatment in participants with primary hypercholesterolemia (familial and nonfamilial) or mixed hyperlipidemia. The study will also evaluate the effect of SCH 900271 on non-high density lipoprotein cholesterol (non-HDL-C) and various other lipids and lipoproteins. The safety of SCH 900271 in this participant population will also be evaluated.

NCT ID: NCT00871351 Completed - Clinical trials for Primary Hypercholesterolemia

Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)

Start date: February 1, 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of atorvastatin 10 mg and ezetimibe 10 mg coadministration in Japanese participants with hypercholesterolemia whose low-density lipoprotein (LDL)-cholesterol levels have not reached the lipid management target value with atorvastatin 10 mg alone, versus increasing the dose of atorvastatin to 20 mg or changing to rosuvastatin 2.5 mg.